Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/16/2022 | $5.00 | Buy | Ladenburg Thalmann |
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief Development Officer effective December 1, 2021 - HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2021 and provided an operational update. "In the third quarter, Bellicum broadened the potential impact of its CaspaCIDe technology through an additional licensing agreement with MD Anderson," said Rick Fair, President and
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company's assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most recent patient treated in the Phase 1/2 trial of BPX-601 in metastatic castration-resistant prostate cancer (mCRPC) experienced serious immune-mediated adverse events including Grade 4 cytokine rel
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and bone involvement HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled "Early Results from a Phase 1, Multicent
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.14 per share and vest over four years, with 25% of the shares vesting on the one-year a
15-12G - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
EFFECT - BELLICUM PHARMACEUTICALS, INC (0001358403) (Filer)
4 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
3 - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
4/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Issuer)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13G/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
SC 13D/A - BELLICUM PHARMACEUTICALS, INC (0001358403) (Subject)
Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals with a rating of Buy and set a new price target of $5.00